PUSH: Helping People with HIV and Substance Use
Part of Immune system & allergy, Infections, Mental health clinical trials.
This study tests if a program that encourages positive activities (behavioral activation) can help people with HIV or on PrEP who also use substances improve their health. It focuses on those receiving long-acting injectable medications for HIV prevention or treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have HIV (and are on treatment) or you are HIV negative (and eligible for PrEP)
- You are using or willing to use a long-acting injectable medication (Cabotegravir/Rilpivirine) for HIV prevention or treatment
- You have moderate substance use (like cocaine, amphetamines, opioids, alcohol) — based on a screening questionnaire
- You are not pregnant or breastfeeding
- You do not have medical conditions that prevent using these injectable medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how to better support young men living with or at risk for HIV while also addressing substance use. You'll work with a care team that helps you stay healthy and connected to services.
This study looks at whether getting support from friends and peers who also use drugs can help people start HIV prevention (PrEP) and treatment for substance use. The goal is to make it easier for people who inject drugs to get the care they need.
This study tests an alcohol- and sexual-health program to help reduce HIV risk in men who recently had condomless sex and drink heavily. It may help you by offering structured support around drinking and HIV prevention (PrEP).
This study tests a program to help Black and Hispanic women with substance use disorders take PrEP consistently to prevent HIV. The goal is to see if talking with a health coach can improve PrEP use and reduce HIV risk.
This Phase 3 study tests whether an injectable HIV prevention medicine (cabotegravir) given before exposure can help prevent HIV in people at higher risk. You may join if you are HIV-negative and meet specific sexual health, medication, and health-testing requirements.
This study tests a long-acting HIV prevention shot (Cabotegravir) or a vaginal ring (DapiRing) along with sexual health services for young people. It aims to find the best way to prevent HIV and support overall health.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.